In mouse transgenic skin cancer models expressing an activating mutant of phosphatidylinositol 3-kinase alpha (PIK3CAH1047R) or HRas (HRasG12V), mutations known to drive human SCC, a RIPK4 kinase-dependent tumor suppressor role was shown [138, 175, 177]. This evidence concerns the gene RIPK4 and skin neoplasm.